China SXT Pharmaceuticals (SXTC) EPS (Weighted Average and Diluted): 2021-2025
- China SXT Pharmaceuticals' EPS (Weighted Average and Diluted) fell 14.98% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.1 million, marking a year-over-year increase of 3.94%. This contributed to the annual value of -$2.32 for FY2025, which is 91.88% up from last year.
- China SXT Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to $26.4 million in Q3 2025, which was up 21.65% from $21.7 million recorded in Q1 2025.
- Over the past 5 years, China SXT Pharmaceuticals' EPS (Weighted Average and Diluted) peaked at $34.5 million during Q1 2021, and registered a low of $14.6 million during Q3 2023.
- Over the past 3 years, China SXT Pharmaceuticals' median EPS (Weighted Average and Diluted) value was $24.7 million (recorded in 2024), while the average stood at $24.4 million.
- Per our database at Business Quant, China SXT Pharmaceuticals' EPS (Weighted Average and Diluted) tumbled by 34.23% in 2023 and then surged by 112.49% in 2024.
- Quarterly analysis of 5 years shows China SXT Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $22.7 million in 2021, then decreased by 2.16% to $22.2 million in 2022, then plummeted by 34.23% to $14.6 million in 2023, then spiked by 112.49% to $31.0 million in 2024, then dropped by 14.98% to $26.4 million in 2025.
- Its last three reported values are $26.4 million in Q3 2025, $21.7 million for Q1 2025, and $31.0 million during Q3 2024.
